Observation of Patients With Transfusional Hemosiderosis Treatment With Deferasirox

Novartis

Status: Completed

Conditions: Transfusional Hemosiderosis

Treatments: Drug: deferasirox

Study type: Observational

Funder types: Industry

Identifiers

NCT01394029

CICL670A2301

Details and patient eligibility

About

This study will observe patients with transfusional hemosiderosis treated with deferasirox in actual practice setting.

Enrollment: 120 patients

Sex: All

Ages: 2+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-Patients treated with deferasirox for transfusional hemosiderosis according to the local prescribing information.

(the patients are either beginning treatment with deferasirox at the time of enrollment in the sentinel site monitoring or are currently under treatment with deferasirox and have started the treatment under prescription up to twelve months prior to enrollment in the sentinal site monitoring.

Exclusion criteria

• Patients with non-transfusional hemosiderosis
• Patients treated with deferasirox in an interventional clinical trial

Other protocol-defined inclusion/exclusion criteria may apply.

Trial design

120 participants in 1 patient group

deferasirox

Treatment:

Drug: deferasirox